Fig. 2From: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLCForest plot visualizing multivariate proportional hazard cox regression model of factors associated with the progression-free survival (PFS) of metastatic NSCLC patientsBack to article page